Clin Colon Rectal Surg 2009; 22(2): 107-114
DOI: 10.1055/s-0029-1223842
© Thieme Medical Publishers

Rare Anorectal Neoplasms: Gastrointestinal Stromal Tumor, Carcinoid, and Lymphoma

Elizabeth A. Peralta1
  • 1Surgical Oncology, Southern Illinois University School of Medicine, Department of Surgery, Springfield, Illinois
Further Information

Publication History

Publication Date:
27 May 2009 (online)

ABSTRACT

Several uncommon tumors occur in the anal canal such as gastrointestinal stromal tumors, carcinoids, and lymphoma. Increased clinical experience and advancements in molecular biology have improved the accuracy of pathologic diagnosis and guided treatment recommendations, which the author addresses in this article.

REFERENCES

  • 1 Madeleine MM, Newcomer LM Cancer of the anus. National Cancer Institute's's Surveillance, Epidemiology, and End Results Program (SEER). Bethesda, MD; National Cancer Institute 2007: 43
  • 2 Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom J M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.  Am J Pathol. 1998;  152(5) 1259-1269
  • 3 Hatch K F, Blanchard D K, Hatch III G F et al.. Tumors of the rectum and anal canal.  World J Surg. 2000;  24(4) 437-443
  • 4 Fletcher C D, Berman J J, Corless C et al.. Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33(5) 459-465
  • 5 Nigri G R, Dente M, Valabrega S et al.. Gastrointestinal stromal tumor of the anal canal: an unusual presentation.  World J Surg Oncol. 2007;  5 20
  • 6 Hirota S, Isozaki K, Moriyama Y et al.. Gain-of-function mutations of C-KIT in human gastrointestinal stromal tumors.  Science. 1998;  279(5350) 577-580
  • 7 Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.  Arch Pathol Lab Med. 2006;  130(10) 1466-1478
  • 8 DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231(1) 51-58
  • 9 Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.  Am J Surg Pathol. 2001;  25(9) 1121-1133
  • 10 Eisenberg B L, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.  Ann Surg Oncol. 2004;  11(5) 465-475
  • 11 Katz S C, DeMatteo R P. Gastrointestinal stromal tumors and leiomyosarcomas.  J Surg Oncol. 2008;  97(4) 350-359
  • 12 Miettinen M, Sarlomo-Rikala M, Sobin L H. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors—a clinicopathologic and immunohistochemical study of eighty-eight cases.  Mod Pathol. 2001;  14(10) 950-956
  • 13 Hassan I, You Y N, Dozois E J et al.. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies.  Dis Colon Rectum. 2006;  49(5) 609-615
  • 14 Tworek J A, Goldblum J R, Weiss S W, Greenson J K, Appelman H D. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases.  Am J Surg Pathol. 1999;  23(8) 946-954
  • 15 Vorobyov G I, Odaryuk T S, Kapuller L L, Shelygin Y A, Kornyak B S. Surgical treatment of benign, myomatous rectal tumors.  Dis Colon Rectum. 1992;  35(4) 328-331
  • 16 Demetri G D, Benjamin R S, Blanke C D NCCN Task Force et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines.  J Natl Compr Canc Netw. 2007;  5(Suppl 2) S1-S29, quiz S30
  • 17 Levy A D, Remotti H E, Thompson W M, Sobin L H, Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation.  AJR Am J Roentgenol. 2003;  180(6) 1607-1612
  • 18 Dematteo R P, Gold J S, Saran L et al.. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).  Cancer. 2008;  112(3) 608-615
  • 19 Haque S, Dean P J. Stromal neoplasms of the rectum and anal canal.  Hum Pathol. 1992;  23(7) 762-767
  • 20 DeMatteo R P, Owzar K, Antonescu C R et al.. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The US. Intergroup Phase II Trial ACOSOG z9000 (Abstract No. 8). Abstract presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium January 25–27, 2008 Orlando, FL;
  • 21 DeMatteo R, Owzar K, Maki R et al.. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III Trial ACOSOG z9001 (Abstract No. 10079). Abstract presented at: 2007 American Society of Clinical Oncology Annual Meeting June 1–5, 2007 Chicago, IL;
  • 22 Walsh T H, Mann C V. Smooth muscle neoplasms of the rectum and anal canal.  Br J Surg. 1984;  71(8) 597-599
  • 23 Changchien C R, Wu M C, Tasi W S et al.. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining.  Dis Colon Rectum. 2004;  47(11) 1922-1929
  • 24 Li J C, Ng S S, Lo A W, Lee J F, Yiu R Y, Leung K L. Outcome of radical excision of anorectal gastrointestinal stromal tumors in Hong Kong Chinese patients.  Indian J Gastroenterol. 2007;  26(1) 33-35
  • 25 Baik S H, Kim N K, Lee C H et al.. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases.  Surg Today. 2007;  37(6) 455-459
  • 26 Chen C W, Wu C C, Hsiao C W et al.. Surgical management and clinical outcome of gastrointestinal stromal tumor of the colon and rectum.  Z Gastroenterol. 2008;  46(8) 760-765
  • 27 Demetri G D, von Mehren M, Blanke C D et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347(7) 472-480
  • 28 Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn J D. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.  Cancer Epidemiol Biomarkers Prev. 2008;  17(8) 2194-2201
  • 29 Hohenberger P. Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?.  Nat Clin Pract Oncol. 2008;  5(5) 240-241
  • 30 Rutkowski P, Nowecki Z, Nyckowski P et al.. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.  J Surg Oncol. 2006;  93(4) 304-311
  • 31 Eisenberg B L, Harris J, Blanke C D et al.. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.  J Surg Oncol. 2009;  99(1) 42-47
  • 32 Demetri G D, van Oosterom A T, Garrett C R et al.. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.  Lancet. 2006;  368(9544) 1329-1338
  • 33 Caldarola V T, Jackman R J, Moertel C G, Dockerty M B. Carcinoid tumors of the rectum.  Am J Surg. 1964;  107 844-849
  • 34 Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases.  Cancer. 2005;  103(8) 1587-1595
  • 35 Landry C S, Brock G, Scoggins C R, McMasters K M, Martin II R C. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients.  Surgery. 2008;  144(3) 460-466
  • 36 Pinchot S N, Holen K, Sippel R S, Chen H. Carcinoid tumors.  Oncologist. 2008;  13(12) 1255-1269
  • 37 Orloff M J. Carcinoid tumors of the rectum.  Cancer. 1971;  28(1) 175-180
  • 38 Oberg K. Carcinoid tumors, the carcinoid syndrome, and related disorders. In: Kronenberg HM Williams Textbook of Endocrinology. Philadelphia, PA; Saunders Elsevier 2008: 1821
  • 39 Memon M A, Nelson H. Gastrointestinal carcinoid tumors: current management strategies.  Dis Colon Rectum. 1997;  40(9) 1101-1118
  • 40 Jetmore A B, Ray J E, Gathright Jr J B, McMullen K M, Hicks T C, Timmcke A E. Rectal carcinoids: the most frequent carcinoid tumor.  Dis Colon Rectum. 1992;  35(8) 717-725
  • 41 Fahy B N, Tang L H, Klimstra D et al.. Carcinoid of the rectum risk stratification (CaRRS): a strategy for preoperative outcome assessment.  Ann Surg Oncol. 2007;  14(2) 396-404
  • 42 Kwaan M R, Goldberg J E, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy.  Arch Surg. 2008;  143(5) 471-475
  • 43 Koura A N, Giacco G G, Curley S A, Skibber J M, Feig B W, Ellis L M. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival.  Cancer. 1997;  79(7) 1294-1298
  • 44 Shepherd N A, Hall P A, Coates P J, Levison D A. Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations.  Histopathology. 1988;  12(3) 235-252
  • 45 Ioachim H L, Antonescu C, Giancotti F, Dorsett B, Weinstein M A. EBV-associated anorectal lymphomas in patients with acquired immune deficiency syndrome.  Am J Surg Pathol. 1997;  21(9) 997-1006
  • 46 Diamond C, Taylor T H, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.  Cancer. 2006;  106(1) 128-135
  • 47 The N CCN. Clinical Practice Guidelines in Oncology™ Non-Hodgkin Lymphoma (Version I. 2009). Fort Washington, PA; National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org Accessed February 15, 2009

Elizabeth A PeraltaM.D. 

Surgical Oncology, Southern Illinois University School of Medicine, Department of Surgery

701 N. First St., P.O. Box 19638, Springfield, IL 62794

Email: eperalta@siumed.edu